Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In fiscal 2026, one Plasma customer accounted for approximately 13% of total net revenues.”
$173M relationship
basisHAE fy2026 · closed 2026-03 $1.3B
FILING10-K0000313143-26-000050cik 0000313143
“In addition, we manufacture our vascular closure devices under a shelter plan service agreement with Offshore International Incorporated (d/b/a Tetakawi) pursuant to which we lease our manufacturing facility in Guaymas, Mexico.”
FILING10-K0000313143-25-000025cik 0000313143
“This revenue decrease was primarily driven by lower sales volumes in North America relating to the previously announced customer transition of CSL Plasma, partially offset by share gains, higher volume and pricing benefits.”
FILING10-K0000313143-26-000050cik 0000313143
“On January 13, 2025, we completed the transaction with GVS for total cash consideration of up to $65.8 million, which includes $43.3 million upfront and up to $22.5 million in contingent consideration, based on sales growth over the next three years and the achievement of certain other milestones.”
FILING10-K0000313143-25-000025cik 0000313143
“Our Blood Center business supports the collection of plasma for blood collectors, such as the American Red Cross, using apheresis collection devices.”
FILING10-K0000313143-26-000050cik 0000313143
“Over the last 20 years, the collection of source plasma has increasingly been performed by vertically integrated biopharmaceutical companies such as Grifols S.A., Octapharma AG, Takeda's BioLife Plasma subsidiary and CSL Limited (together with its affiliates, "CSL").”
FILING10-K0000313143-26-000050cik 0000313143
“Over the last 20 years, the collection of source plasma has increasingly been performed by vertically integrated biopharmaceutical companies such as Grifols S.A., Octapharma AG, Takeda's BioLife Plasma subsidiary and CSL Limited (together with its affiliates, "CSL").”
FILING10-K0000313143-26-000050cik 0000313143
“Over the last 20 years, the collection of source plasma has increasingly been performed by vertically integrated biopharmaceutical companies such as Grifols S.A., Octapharma AG, Takeda's BioLife Plasma subsidiary and CSL Limited (together with its affiliates, "CSL").”
FILING10-K0000313143-26-000050cik 0000313143
“Over the last 20 years, the collection of source plasma has increasingly been performed by vertically integrated biopharmaceutical companies such as Grifols S.A., Octapharma AG, Takeda's BioLife Plasma subsidiary and CSL Limited (together with its affiliates, "CSL").”
FILING10-K0000313143-26-000050cik 0000313143
Watchlist prices, news filtered to it, and its next report on your desk.
Haemonetics Corp has 1 disclosed supplier and 8 disclosed customers, each named in an SEC filing with the sentence that discloses it.
HAE (Haemonetics Corp) has 1 disclosed suppliers and 8 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
Haemonetics Corp
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Surgical & Medical Instruments & Apparatus
High 107.00 at 8:00 am ET, low 105.02 at 3:00 pm ET.